Related Experiment Video

Updated: May 29, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study

Giovanni Della Cioppa1, Timo Vesikari, Etienne Sokal

  • 1Vaccines Development, Novartis Vaccines and Diagnostics, Siena, Italy. giovanni.della cioppa@novartis.com

Vaccine
|September 13, 2011
PubMed

Insights

Adjuvanted quadrivalent influenza vaccines (QIV) show promising safety and immunogenicity in young children. MF59 adjuvant boosts antibody responses, offering potential advantages for pediatric influenza protection.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Young children face high risks of influenza infection and complications.
  • Conventional trivalent inactivated influenza vaccines (TIV) offer suboptimal protection in this age group, especially against influenza B strains.

Purpose of the Study:

  • To evaluate the safety and immunogenicity of adjuvanted (ATIV) and non-adjuvanted trivalent (TIV) and quadrivalent (QIV) influenza vaccines.
  • To assess different vaccine combinations in healthy children aged 6 to <36 months.

Main Methods:

  • A dose-ranging, factorial design trial involving 480 healthy children.
  • Administration of various combinations of adjuvanted and non-adjuvanted TIV and QIV.
  • Assessment of safety, tolerability, and immunogenicity through antibody response measurements.

Main Results:

  • The addition of a second B strain to TIV was immunogenic and did not impact the immunogenicity of other strains.
  • MF59 adjuvant significantly enhanced immune responses, with elevated antibodies observed even after a single dose.
  • A dose-response relationship was noted between antibody response and MF59 adjuvant presence.
  • No specific safety or tolerability patterns were associated with different adjuvant/antigen doses or the inclusion of a second B strain.

Conclusions:

  • MF59-adjuvanted quadrivalent influenza vaccine (QIV) demonstrates potential benefits for enhancing influenza protection in young children.
  • Adjuvanted QIV may offer improved immunogenicity and antibody responses compared to conventional vaccines in the pediatric population.

More Related Videos

Measuring Influenza Neutralizing Antibody Responses to A(H3N2) Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells12:09

Measuring Influenza Neutralizing Antibody Responses to A(H3N2) Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells

Published on: November 22, 2017

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers06:34

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to individual...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...